In melanoma patients, the anti-TIM-3 antibody restored the T cell function of TIM-3+CD4+ and CD8+ cells, and these cells contribute to the TME [36], which suggests a certain connection between TIM-3 and cancer progression. Here, CD8A is linked to cancer.